Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Stem Cell Rev Rep. 2022 Oct;18(7):2209-2233. doi: 10.1007/s12015-022-10426-9. Epub 2022 Jul 25.
The physiological state of the tumor microenvironment (TME) plays a central role in cancer development due to multiple universal features that transcend heterogeneity and niche specifications, like promoting cancer progression and metastasis. As a result of their preponderant involvement in tumor growth and maintenance through several microsystemic alterations, including hypoxia, oxidative stress, and acidosis, TMEs make for ideal targets in both diagnostic and therapeutic ventures. Correspondingly, methodologies to target TMEs have been investigated this past decade as stratagems of significant potential in the genre of focused cancer treatment. Within targeted oncotherapy, nanomedical derivates-nanocarriers (NCs) especially-have emerged to present notable prospects in enhancing targeting specificity. Yet, one major issue in the application of NCs in microenvironmental directed therapy is that TMEs are too broad a spectrum of targeting possibilities for these carriers to be effectively employed. However, cancer stem cells (CSCs) might portend a solution to the above conundrum: aside from being quite heavily invested in tumorigenesis and therapeutic resistance, CSCs also show self-renewal and fluid clonogenic properties that often define specific TME niches. Further scrutiny of the relationship between CSCs and TMEs also points towards mechanisms that underly tumoral characteristics of metastasis, malignancy, and even resistance. This review summarizes recent advances in NC-enabled targeting of CSCs for more holistic strikes against TMEs and discusses both the current challenges that hinder the clinical application of these strategies as well as the avenues that can further CSC-targeting initiatives. Central role of CSCs in regulation of cellular components within the TME.
肿瘤微环境 (TME) 的生理状态在癌症发展中起着核心作用,这是由于其具有多种普遍特征,超越了异质性和小生境特异性,如促进癌症进展和转移。由于它们通过多种微系统改变(包括缺氧、氧化应激和酸中毒)在肿瘤生长和维持中占主导地位,TME 成为诊断和治疗探索的理想靶点。因此,过去十年一直在研究针对 TME 的方法,作为聚焦癌症治疗领域具有重要潜力的策略。在靶向肿瘤治疗中,纳米医学衍生物-纳米载体 (NCs) 尤其具有增强靶向特异性的显著前景。然而,NC 在微环境导向治疗中的应用存在一个主要问题,即 TME 是一个广泛的靶向可能性范围,这些载体无法有效地被利用。然而,癌症干细胞 (CSC) 可能为解决上述难题提供了一种解决方案:除了在肿瘤发生和治疗抵抗中投入大量资金外,CSC 还表现出自更新和流体克隆形成特性,这些特性通常定义了特定的 TME 小生境。对 CSC 和 TME 之间关系的进一步研究也指向了肿瘤转移、恶性和甚至耐药性的肿瘤特征背后的机制。本综述总结了最近在 NC 靶向 CSC 方面的进展,以更全面地针对 TME,并讨论了阻碍这些策略临床应用的当前挑战以及可以进一步推进 CSC 靶向的途径。CSC 在调节 TME 中细胞成分方面的核心作用。